OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
15 mai 2023 16h15 HE
|
OpGen, Inc.
Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero...
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
18 avr. 2023 16h30 HE
|
OpGen, Inc.
Fisher Healthcare, a part of Thermo Fisher Scientific, will become the non-exclusive national laboratory distribution partner alongside OpGen, Inc.’s direct sales in the U.S. for the Unyvero A50...
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel
18 avr. 2023 07h30 HE
|
OpGen, Inc.
Based on large multi-center study with over 1,800 patient samplesPrimary endpoint for Unyvero UTI for urinary tract infection was successfully met and shows overall weighted average sensitivity of...
CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
30 mars 2023 14h25 HE
|
OpGen, Inc.
ROCKVILLE, Md., March 30, 2023 (GLOBE NEWSWIRE) -- In a release published March 29, 2023 under the same headline by OpGen, Inc. (Nasdaq: OPGN), the financial tables were incorrect. The corrected...
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
29 mars 2023 16h15 HE
|
OpGen, Inc.
Total revenue for 2022 was approximately $2.6 millionBalance sheet strengthened by recently closed public offering with gross proceeds of $7.5 millionConference call to be held March 29, 2023 at 4:30...
NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia
19 mai 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation...